The susceptibility to chronic social defeat stress is related to low hippocampal extrasynaptic NMDA receptor function.


Journal

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907

Informations de publication

Date de publication:
06 2019
Historique:
received: 16 07 2018
accepted: 19 01 2019
revised: 16 01 2019
pubmed: 7 2 2019
medline: 18 12 2019
entrez: 7 2 2019
Statut: ppublish

Résumé

N-methyl-D-aspartate receptors (NMDARs) have been highly implicated in the pathogenesis and treatment of depression. While NMDARs can be found inside and outside glutamate synapses, it remains unclear if NMDARs at synaptic (sNMDAR) and extrasynaptic locations (exNMDAR) play different roles in the formation of depression-related behaviors. Using chronic social defeat stress (CSDS), an animal model for anxiety- and depression-related behaviors, we found that mice susceptible to CSDS exhibited low hippocampal exNMDAR function. Raising exNMDAR function by enhancing the release of glutamate from astrocytic cystine-glutamate antiporters or targeting extrasynaptic receptors with agonist-coated gold nanoparticles that cannot enter the synaptic cleft prevented social avoidance behavior in stressed mice. Interestingly, ketamine, which is a fast-acting antidepressant, exhibited stronger blockade to sNMDARs than to exNMDARs. These findings suggest that the susceptibility and resilience of mice toward CSDS is related to low and high exNMDAR function in the hippocampus, respectively. Enhancing exNMDAR function could be a novel treatment approach for mood and anxiety disorders.

Identifiants

pubmed: 30723288
doi: 10.1038/s41386-019-0325-8
pii: 10.1038/s41386-019-0325-8
pmc: PMC6785155
doi:

Substances chimiques

Receptors, N-Methyl-D-Aspartate 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1310-1318

Subventions

Organisme : Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada)
ID : 137003
Pays : International

Références

Nat Rev Neurosci. 2010 Oct;11(10):682-96
pubmed: 20842175
J Neurosci. 2008 Jun 25;28(26):6659-63
pubmed: 18579739
Nat Med. 2009 Dec;15(12):1407-13
pubmed: 19915593
Biol Psychiatry. 2014 Oct 1;76(7):550-8
pubmed: 24495460
Biol Psychiatry. 2000 Feb 15;47(4):305-13
pubmed: 10686265
Neuropharmacology. 2010 Feb;58(2):465-73
pubmed: 19747495
Neuropsychopharmacology. 2012 Dec;37(13):2797-808
pubmed: 22871917
Nano Lett. 2016 Sep 14;16(9):5495-502
pubmed: 27490923
Front Neurosci. 2018 Aug 29;12:613
pubmed: 30210285
Neurosci Biobehav Rev. 2015 Aug;55:294-321
pubmed: 25957927
Curr Drug Targets. 2013 Oct;14(11):1225-36
pubmed: 23469922
Trends Pharmacol Sci. 2013 Mar;34(3):167-77
pubmed: 23369637
Cell Rep. 2012 May 31;1(5):495-505
pubmed: 22832274
Hippocampus. 2014 Sep;24(9):1120-8
pubmed: 24753271
Biol Psychiatry. 2013 Nov 15;74(10):734-41
pubmed: 23562005
J Neurosci. 2005 Apr 27;25(17):4288-93
pubmed: 15858055
Psychopharmacology (Berl). 2012 Nov;224(2):313-25
pubmed: 22707231
Neuron. 2014 Apr 16;82(2):279-93
pubmed: 24742457
Curr Protein Pept Sci. 2017 Aug 30;18(11):1152-1162
pubmed: 28699511
J Physiol. 2007 Apr 15;580(Pt. 2):373-83
pubmed: 17185337
Science. 2006 Feb 10;311(5762):864-8
pubmed: 16469931
Eur J Neurosci. 2008 Aug;28(3):521-34
pubmed: 18702724
Nature. 2017 Jun 21;546(7659):E1-E3
pubmed: 28640258
Biol Psychiatry. 2017 May 15;81(10):886-897
pubmed: 27449797
Psychiatry Res. 2006 Jun 30;147(1):1-25
pubmed: 16806850
J Mol Neurosci. 2007;33(2):201-15
pubmed: 17917079
Sci Transl Med. 2017 Dec 20;9(421):
pubmed: 29263233
Neuropsychopharmacology. 2014 Apr;39(5):1148-58
pubmed: 24213355
Neuropsychopharmacology. 2007 Sep;32(9):1888-902
pubmed: 17299517
Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1823-8
pubmed: 17261811
Physiol Behav. 2012 Feb 1;105(3):749-56
pubmed: 22008744
ACS Nano. 2011 Nov 22;5(11):8629-39
pubmed: 21974862
Cell. 2007 Oct 19;131(2):391-404
pubmed: 17956738
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3573-8
pubmed: 23401542
Biol Psychiatry. 2013 Jun 15;73(12):1133-41
pubmed: 23726151
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4436-41
pubmed: 20176946
J Neurosci. 2016 Mar 23;36(12):3481-94
pubmed: 27013677
J Neurosci. 2009 Jul 22;29(29):9330-43
pubmed: 19625523
J Clin Psychopharmacol. 2012 Aug;32(4):551-7
pubmed: 22722512
Nature. 2016 May 04;533(7604):481-6
pubmed: 27144355
Cell Mol Life Sci. 2003 Jan;60(1):6-20
pubmed: 12613655
Curr Opin Neurobiol. 2001 Jun;11(3):327-35
pubmed: 11399431
Sci Rep. 2017 Aug 14;7(1):8053
pubmed: 28808323
Neuron. 2010 Jan 28;65(2):178-90
pubmed: 20152125
J Neuroendocrinol. 2010 Nov;22(11):1187-97
pubmed: 20735798
Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8649-54
pubmed: 24912158
Front Physiol. 2012 Aug 24;3:334
pubmed: 22934081
Nat Commun. 2015 May 08;6:7062
pubmed: 25952660
Neuron. 2017 Oct 11;96(2):402-413.e5
pubmed: 29024663
Nat Med. 2012 Sep;18(9):1413-7
pubmed: 22885997
Brain Res Bull. 2013 Apr;93:10-6
pubmed: 23270879
Biol Psychiatry. 2018 Jan 1;83(1):9-17
pubmed: 28888327
Front Mol Neurosci. 2018 Aug 06;11:251
pubmed: 30127715
J Neurosci. 2010 Dec 15;30(50):16949-58
pubmed: 21159965
J Physiol. 2007 Oct 15;584(Pt 2):509-19
pubmed: 17717018
J Neurosci. 2017 Aug 9;37(32):7656-7668
pubmed: 28674176
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:28-33
pubmed: 23643674
Ther Adv Chronic Dis. 2015 May;6(3):97-114
pubmed: 25954495
Neuropsychopharmacology. 2003 Apr;28(4):720-5
pubmed: 12655317
Int J Neuropsychopharmacol. 2013 Apr;16(3):501-6
pubmed: 23174090
PLoS One. 2011;6(11):e27215
pubmed: 22069501
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11471-6
pubmed: 17592137
Biol Psychiatry. 2009 Jan 15;65(2):150-9
pubmed: 18823877

Auteurs

Yiu Chung Tse (YC)

Douglas Mental Health University Institute, 6875 LaSalle Blvd, Montreal, QC, Canada.

Joëlle Lopez (J)

Douglas Mental Health University Institute, 6875 LaSalle Blvd, Montreal, QC, Canada.

Alexandre Moquin (A)

Department of Pharmacology & Therapeutics, McGill University, Montreal, QC, Canada.

Shui-Ming Alice Wong (SA)

Douglas Mental Health University Institute, 6875 LaSalle Blvd, Montreal, QC, Canada.

Dusica Maysinger (D)

Department of Pharmacology & Therapeutics, McGill University, Montreal, QC, Canada.

Tak Pan Wong (TP)

Douglas Mental Health University Institute, 6875 LaSalle Blvd, Montreal, QC, Canada. takpan.wong@mcgill.ca.
Department of Psychiatry, McGill University, Montreal, QC, Canada. takpan.wong@mcgill.ca.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH